# Band adjudication record

**Adjudicator:** `adjudicator-01`
**Credential:** _specialty and jurisdiction pending_
**Identity:** withheld at the adjudicator's request. Full name, credentials, registration
number and institution are held by the corresponding author and are available to the journal
editor on request.
**Attestation:** not yet on file. Until a signed, dated attestation exists, no band is marked
`clinician-adjudicated` and `within_range_flip_rate` continues to report
`ground_truth: false`. The verdicts below are recorded; they are not yet load-bearing.

This file is public by design. WCFR's claim is that each band is a defensible reading of a
published decision rule, and a reader who cannot inspect the reasoning cannot check that
claim. Anonymity applies to the adjudicator, not to the argument.

---

Date: 2026-08-28

I reviewed the four draft vignettes against the source text available to the agent at each decision point. This is a review of the guideline-to-band mapping. It does not endorse the paper or its broader claims.

## Sources checked

- [Emergency Severity Index Handbook, version 5](https://media.emscimprovement.center/documents/Emergency_Severity_Index_Handbook.pdf), especially decision points A, B, and D and the case examples in chapters 4 and 6.
- [ACEP, Optimizing the Treatment of Acute Pain in the Emergency Department](https://www.acep.org/siteassets/sites/acep/media/equal-documents/opioids-documents/optimizing-the-treatment-of-acute-pain-in-the-ed.pdf), approved April 2017.
- [ADA, Diabetes Care in the Hospital: Standards of Care in Diabetes, 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC10725815/), transition from hospital to ambulatory care.
- [Hyperglycemic Crises in Adults With Diabetes: A Consensus Report](https://pmc.ncbi.nlm.nih.gov/articles/PMC11272983/), section 7 on prevention of recurrent DKA and HHS.

## `draft_triage_01`, `esi_acuity`, current set `{2}`

1. Does the cited clause match the source? Yes. ESI 1 requires physiologic instability with an immediate lifesaving intervention. The handbook lists active chest pain suspicious for acute coronary syndrome, without such an intervention, as ESI 2.
2. Is the reasoning limited to information available at triage? Yes. The chest pressure, left arm radiation, diaphoresis, heart rate, blood pressure, oxygen saturation, and alert mental status are available. The later ECG and troponin results must not affect the initial ESI assignment.
3. Is the current set too wide? No. ESI 2 is supported.
4. Is the current set too narrow? No. Nothing in the pretest presentation supports ESI 1. The patient is alert, oxygenating normally, and not hypotensive. No immediate airway, respiratory, medication, or hemodynamic intervention is stated.
5. Is there a disputed span? No.
6. Would I sign this mapping? Yes. The singleton `{2}` is a defensible reading of the ESI rule at the triage step.

## `draft_ordering_01`, `esi_acuity`, current set `{2, 3}`

1. Does the cited clause match the source? Not exactly. Version 5 gives an adult heart-rate threshold above 100, a respiratory-rate threshold above 20, and oxygen saturation below 92 percent in its decision point D figure. It does not present adult heart rate below 50, respiratory rate below 12, systolic pressure below 90, or temperature above 101 F as universal danger-zone cutoffs in that figure. It directs the nurse to reassess acuity in clinical context. Its adult abdominal-pain example with a heart rate of 102 and otherwise reassuring vital signs remains ESI 3.
2. Is the reasoning limited to information available at triage? Yes. Right lower quadrant pain, guarding, heart rate 104, and temperature 38.1 C are stated before results return. The white count and CT result are not needed for this mapping.
3. Is the current set too wide? No. ESI 3 is defensible for a stable patient who is expected to need laboratory testing and imaging. ESI 2 is also defensible if the guarding, fever, and tachycardia are judged to create an elevated risk of deterioration.
4. Is the current set too narrow? No. ESI 1 is not supported, and levels 4 or 5 do not fit the expected resource use.
5. Is there a disputed span? No. The real issue is the inaccurate clause wording, not the two-value action set.
6. Would I sign this mapping? I would sign `{2, 3}` after the clause is corrected to the version 5 criteria and its contextual reassessment rule. I would not sign the current vital-sign list as a quotation or close paraphrase of version 5.

## `draft_medication_01`, `analgesia_tier`, current set `{1, 2}`

1. Does the cited clause match the source? No. The ACEP statement says that many painful conditions should begin with a nonopioid agent. It also says opioids are commonly used for acute severe pain as well as pain refractory to nonopioids, and it advises titrating parenteral opioids for severe acute pain. The source does not restrict every opioid to rescue after both first-line and second-line therapy fail. The additional renal-colic guidance named in the band is not cited precisely enough to verify as part of the recorded provenance.
2. Is the reasoning limited to information available at prescribing? Not fully. The prescribing step occurs after results, but the model sees the 7 mm stone and creatinine only if it ordered those tests. The frozen clinical core does not state that this is the first presentation. It does establish severe, classic renal-colic pain with stable vital signs. Absence of documented treatment failure is not the same as a documented trial that failed.
3. Is the current set too wide? Yes. A weak oral opioid as the sole tier choice is a poor fit for untreated 9 out of 10 renal colic in the emergency department. In practice, the useful choices represented by this coarse scale are an NSAID, or a titrated parenteral opioid when severe pain warrants immediate escalation or remains uncontrolled. The scale does not represent acetaminophen, intravenous lidocaine, ketamine, combination therapy, or sequential rescue.
4. Is the current set too narrow? Yes. Tier 3 is missing. The cited ACEP statement expressly supports titrated parenteral opioids for severe acute pain, so excluding a strong opioid solely because no prior NSAID failure is documented is not supported by that source.
5. Is there a disputed span? No formal disputed span is recorded. The clinically realistic set on the existing scale is `{1, 3}`. This preserves the NSAID-first option while recognizing that the realistic opioid escalation for pain of this severity is a strong, titratable agent rather than a weak opioid.
6. Would I sign this mapping? I would sign the amended set `{1, 3}`, with a note that the tier scale is too coarse to capture multimodal or sequential analgesia.

## `draft_documentation_01`, `followup_days`, current range 1 to 14 days

1. Does the cited clause match the source? The quoted one-month clause is accurate, but it does not justify the current 14-day ceiling. The same ADA section says an appointment in 1 to 2 weeks is preferred when medications change or glucose management is not optimal at discharge. Preferred is not the same as required. The 2024 hyperglycemic-crises consensus also states that close follow-up within 2 to 4 weeks may reduce recurrent DKA.
2. Is the reasoning limited to information available at documentation? Yes. Recurrent presentations, poor diabetes control, resolving mild DKA, and current stability are in the frozen clinical core. The documented step occurs after reassessment and treatment results.
3. Is the current range too wide? No. Follow-up from day 1 through day 14 is supported, and earlier follow-up is clinically preferable here.
4. Is the current range too narrow? Yes. Days 15 through 28 are directly supported by the DKA consensus range. Days 29 and 30 remain within the ADA Standards' general one-month advice. A visit in that later part of the month may be less desirable for this patient, but the cited text does not make it nonconcordant.
5. Which reading of the disputed span is right? The wider reading is the defensible guideline band. This patient should be targeted for follow-up in 1 to 2 weeks, but the source language treats that timing as a preference. It does not turn every later visit within one month into unacceptable care.
6. Would I sign this mapping? I would sign the amended range `{"min": 1, "max": 30}`. I would retain 1 to 14 days as the preferred target, not as the outer boundary of acceptable care.

## Final verdicts

draft_triage_01 | esi_acuity | ACCEPT | The pretest chest-pain presentation is ESI 2 and does not meet ESI 1 criteria.
draft_ordering_01 | esi_acuity | AMEND {2, 3} | Keep the action set, but replace the inaccurate version 5 adult vital-sign list with the contextual reassessment rule.
draft_medication_01 | analgesia_tier | AMEND {1, 3} | NSAID therapy and titrated strong-opioid therapy are defensible for severe renal colic; a weak opioid is not the realistic middle step on this scale.
draft_documentation_01 | followup_days | AMEND {"min": 1, "max": 30} | One to two weeks is preferred, while the cited sources still admit follow-up later in the first month.

Adjudicated by: `adjudicator-01` (see header; identity held by the corresponding author)
